Current Sleep Research
Narcolepsy with Cataplexy Oral Agent
Axsome Therapeutics: 7-to-10-week randomized study investigating reboxetine, a drug already approved in Europe and Australia to treat narcolepsy w/ cataplexy. Patients may receive compensation for completion of the trial as well as the opportunity to receive the study medication at no cost after the trial period has finished. There are 6 in person visits throughout the study and 2 telephone calls.
To learn more, and to see if you might qualify, please visit www.SYMPHONYstudy.com. ClinicalTrials.gov Identifier: NCT05059223
Soon to Begin Enrolling
- Idiopathic Hypersomnia Oral Agent
- Shift Work Disorder Oral Agent
Clinical Study Interest Form
If you are interested in participating in one of our Sleep Clinical Trials, please complete and submit the Interest Form and one of our study coordinators will contact you with more information.
Closed to Enrollment
Idiopathic Hypersomnia Oral Agent
Harmony Biosciences: 12-to-15-week reverse randomized study for pitolisant (Wakix), a drug approved already to treat narcolepsy that is now being investigated to treat Idiopathic Hypersomnia. Patients start the trial by taking the medication and are randomized for a wash out period. After the study, patients are offered to continue receiving the study medication at no cost. There are 5 in person visits throughout the study and 7 telephone calls. Patients may receive compensation for completion of the trial.